Verrica Pharmaceuticals

$10.89
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.90 (-7.63%) Today

$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell VRCA and other stocks, options, and ETFs commission-free!

About VRCA

Verrica Pharmaceuticals, Inc. operates as a clinical-stage medical dermatology company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its lead product VP-102, is a proprietary topical therapy used in common skin indications including Molluscum contagiosum and Verruca Vulgaris. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA. The listed name for VRCA is Verrica Pharmaceuticals Inc. Common Stock.

CEO

Ted White

Employees

Headquarters

West Chester, Pennsylvania

Founded

2013

Market Cap

251.10M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

73.05K

High Today

$11.73

Low Today

$10.76

Open Price

$11.61

Volume

65.98K

52 Week High

$17.60

52 Week Low

$6.02

Collections

VRCA Earnings

-$0.42

-$0.28

-$0.14

-$0.00

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Mar 11, Pre-Market